Xconomy

SEPTEMBER 11, 2019

GlaxoSmithKline is acquiring a startup it helped launch in 2013 as part of an alliance with life sciences venture capital firm Avalon Ventures. Avalon said Tuesday that GSK (NYSE: GSK ) has agreed to buy the company, Sitari Pharmaceuticals, which has been developing a treatment for celiac disease.

Avalon 56

Avalon Invest Develop Development 56

socalTECH

JULY 14, 2014

Otonomy is venture backed by Avalon Ventures, OrbiMed, Novo A/S, TPG Biotechnology Partners, Domain Associates, Rivervest Venture Partners, and others. otonomy biopharmaceuticals biotech lifescience merger acquisition inner disease exit' Morgan, BofA Merrill Lynch, Piper Jaffray, and Sanford C. READ MORE>>.

Avalon 147

Avalon San Diego Acquisition Marketing 147

socalTECH

JANUARY 17, 2017

AnaptysBio is backed by Frazier Healthcare, Novo A/S, Avalon Ventures, Alloy Ventures, Biotechnology Value Fund, HBM Healthcare Investments, and others. The company is selling 4,000,000 shares of its common stock on the NASDAQ Global Select Market as ANAB. as early as Thursday.

Pricing 100

Pricing Avalon Southern California Venice 100

socalTECH

AUGUST 13, 2014

Otonomy was backed by Avalon Ventures, OrbiMed, Novo A/S, TPG Biotechnology Partners, Domain Associates, and Rivervest Venture Partners. otonomy merger acquisition biotech lifescience otic nasdaq exit' The company priced at the high end of its initial estimated IPO range, which was $14.00 READ MORE>>.

Avalon 138

Avalon San Diego Pricing Acquisition 138

socalTECH

DECEMBER 2, 2013

Inogen is venture backed by Novo A/S, Versant Ventures, Arboretum Ventures, Avalon Ventures, AMV Partners, and others. inogen merger acquisition copd ingn portable oxygen concentrator lifescience medical device' The company''s IPO is being underwritten by J.P. Morgan, Leerink Swann, William Blair, and Stifel. READ MORE>>.

Avalon 153

Avalon Acquisition Marketing Develop 153

socalTECH

AUGUST 4, 2014

The company is venture backed by Avalon Ventures, OrbiMed, Novo AS, TPG Biotech, Domain Associates, Rivervest Venture Partners, as well as others. otonomy biopharmaceuticals biotech lifescience merger acquisition inner disease exit otic pricing' The company indicated in a filing that it now expects its IPO at between $14.00 and $16.00

Pricing 147

Pricing Avalon San Diego Acquisition 147

socalTECH

NOVEMBER 3, 2014

Proximal Data was venture backed by Divergent Ventures and Avalon Ventures, and had only announced around $5M in funding. proximal data samsung electronics merger acquisition cache caching software storage memory hardware' Financial terms of the buy were not announced. READ MORE>>.

Avalon 138

Avalon San Diego Software Acquisition 138

socalTECH

NOVEMBER 13, 2019

San Diego-based COI Pharmaceuticals , the life sciences incubator and support entity created by Avalon Ventures to support its portfolio companies, says that one of its companies, Calporta Therapeutics , has been acquired by Merck. The deal is worth up to $576M, including upfront payments and contingent milestone payments.

Avalon 124

Avalon San Diego Incubator Technology 124

socalTECH

APRIL 1, 2013

The funding came from Divergent Ventures, along with existing investors Avalon Ventures. Bolt was most recently at Avamar Technologies, where he was CTO of the firm before its acquisition by EMC in 2006. The firm said the new funding brings its total raised to $5M. The firm is led by Rory Bolt. READ MORE>>.

Software 124

Software Avalon San Diego Design 124

socalTECH

JULY 16, 2013

The firm recently made an investment in TIO Networks, a bill payment company based in Vancouver, BC, as part of an acquisition of bill payment services provider Globex Financial Services. The fund has not yet announced local investments, but has been actively talking to companies fitting its investment profile.

Capital 174

Capital Southern California Avalon SoCalTech 174

socalTECH

JANUARY 26, 2017

AnaptysBio is backed by Frazier Healthcare, Novo A/S, Avalon Ventures, Alloy Ventures, Biotechnology Value Fund, HBM Healthcare Investments, and others. Anaptys priced its IPO on Wednesday night at $15.00 per share, at the midpoint of its $14.00 estimated IPO range, and closed the day at $17.00 READ MORE>>.

Avalon 100

Avalon San Diego Pricing Invest 100

socalTECH

MAY 27, 2009

Financial terms of the acquisition were not disclosed. According to Redwood City-based Good Technology, the acquisition will further expand its device portfolio and enhance the capabilities of its solutions. Tags: telecom mobile acquisition merger technology good interacasting. READ MORE>>.

Technology 100

Technology Avalon Anthem Social Network 100

socalTECH

JULY 21, 2011

Amira Pharmaceuticals was venture backed by Avalon Ventures, Novo A/S,Prospect Venture Partners, and Versant Ventures. San Diego-based Amira Pharmaceuticals , a developer of small molecule pharmaceuticals for treating inflammatory and fibrotic diseases, has agreed to be acquired by Bristol-Myers Squibb , the firms said late Thursday.

Avalon 150

Avalon San Diego Venture Capital Capital 150

socalTECH

DECEMBER 16, 2011

Among the biggest winners of the IPO of Zynga is San Diego-based Avalon Ventures , which owned 32,169,401 shares of Zynga before the IPO, a stake which was worth $321M based on Zynga's opening price this morning. Zynga looks to be among the most visible exits from that firm's portfolio yet.

Southern California 145

Southern California SoCal Avalon San Diego 145

Xconomy

FEBRUARY 26, 2020

About three years ago fledgling San Diego-based startup PvP Biologics announced a $35 million deal with Takeda Pharmaceutical that gave the Japan pharma giant rights to acquire the company down the line. That day is here.

San Diego 72

San Diego Study Develop Development 72